Bio-Techne (TECH) balance sheet and financial health

Life Sciences Tools & Services · NASDAQ · Health Care

$72.63 -0.22% Close Nov 17, 2026 Live

TrendArc score 46 of 100 · Health 5.9 · Momentum 7.0 · Moat 3.9 · scored Nov 17, 2026 · How the score works

Cash and short-term investments less borrowings, September 30, 2026

$150 million more cash than borrowings

Bio-Techne held $350 million of cash and short-term investments against $200 million of borrowings on September 30, 2026. Its lease liabilities, shown apart from borrowings, were $86 million. In the fiscal year to June 2026 its operating income covered its interest 26.2 times.

Borrowings to equity

0.09

$200M of borrowings on $2.17B of equity, Sep 2026

Interest cover

26.2x

operating income over interest, fiscal year to June 2026

Return on invested capital

5.1%

latest quarter to September 2026, annualised; the stock card's measure

Cash and borrowings at each fiscal year end

$200M$400M$600M2017201820192020202120222023202420252026Cash and short-terminvestments $265MBorrowings $200M$200M$400M$600M20182020202220242026Cash and short-term investments $265MBorrowings $200M

What the balance sheet holdsSeptember 30, 2026

Assets $2.64BCash and short-term investments$350MReceivables$203MInventory$198MOther current assets$74.1MProperty, goodwill and other$1.81BFunded by $2.64BBorrowings$200MLease liabilities$85.6MOther liabilities$186MShareholders' equity$2.17BAssets $2.64BCash and short-term investments$350MReceivables$203MInventory$198MOther current assets$74.1MProperty, goodwill and other$1.81BFunded by $2.64BBorrowings$200MLease liabilities$85.6MOther liabilities$186MShareholders' equity$2.17B

"Other liabilities" is total liabilities less borrowings and lease liabilities; "Property, goodwill and other" is total assets less the current assets and long-term investments.

Balance sheet, the last 10 fiscal year ends

In billions of US dollars, at each fiscal year end, named by the month it ended; the first column is the newest balance sheet on file. Borrowings are bonds, notes, loans and commercial paper; lease liabilities, operating and finance, are shown apart.
Fiscal year endLatest
Sep 2026
Jun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
Assets
Cash and short-term investments0.350.260.160.150.200.250.230.270.170.180.16
Receivables0.200.220.210.240.220.190.150.120.140.120.12
Inventory0.200.200.190.180.170.140.120.100.090.090.06
Other current assets0.070.070.050.040.030.020.020.020.020.010.01
Total current assets0.820.740.610.620.620.610.510.520.410.400.35
Long-term investments0.000.000.000.000.000.000.000.000.000.000.00
Total assets2.642.592.562.702.642.292.262.031.881.591.56
Liabilities and equity
Current liabilities0.360.160.180.160.130.180.150.110.100.080.14
Borrowings0.200.200.350.320.350.260.340.360.510.340.34
Lease liabilities0.090.090.100.100.100.070.080.08———
Total liabilities0.470.480.640.640.670.590.690.650.720.510.61
Shareholders' equity2.172.111.922.071.971.701.561.381.171.080.95
Financial health
Cash less borrowings0.150.06-0.18-0.17-0.15-0.01-0.11-0.09-0.34-0.16-0.19
Borrowings to equity0.090.090.180.150.180.150.220.260.430.310.36
Interest cover—26.2x12.0x13.1x26.7x26.2x17.0x8.2x6.8x13.4x16.4x

Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.

Bio-Techne against its peers

CompanyCash less borrowingsBorrowings to equityInterest coverReturn on invested capital
Bio-TechneTECH +$150M 0.09 26.2x 5.1%
IlluminaILMN -$452M 0.57 8.0x 16.4%
Mettler ToledoMTD -$1.97B 26.06 16.1x 48.2%
Agilent TechnologiesA -$2.19B 0.54 13.2x 13.2%
Charles River LaboratoriesCRL -$2.24B 0.76 0.2x 21.9%
WatersWAT -$4.54B 0.34 11.5x 1.6%
IQVIAIQV -$13.6B 2.41 3.0x 6.4%

Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.

Next

Follow Bio-Techne with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Bio-Techne from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.